Swiecicki L.,Instytut Psychiatrii i Neurologii
Psychiatria | Year: 2013
This paper presents main practical aspects of pharmacotherapy of anxiety disorders. Particular attention was devoted to role of opipramol and to results of trials which indicate the usefullness of this drug in therapy of anxiety and somatoform disorders. © Copyright 2013 Via Medica. Source
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.3.1-1 | Award Amount: 6.39M | Year: 2014
Mental disorders affect 38.2% of the EU population. For reducing the associated burden, countries across Europe engage in costly re-organizations of mental health care systems. Reforms focus on one controversial core question: Should systems be functional or integrated? In functional systems, separate staff in different services are in charge of in- and out-patient care (to enhance specialization). In integrated systems, the same staff are responsible across services (to strengthen co-ordination and avoid fragmentation). So far, there is no sound research evidence to inform the debate and far reaching policy decisions. Integrated and functional systems co-exist in some countries. This provides the unique chance to compare the effectiveness of the two systems independently of country specific contexts. We will conduct a large-scale comparison in countries with different traditions, levels of service provision and funding systems of mental health care (Belgium, Germany, Italy, Poland, United Kingdom). We will work as a multi-disciplinary team (psychiatrists, psychologists, nurses, sociologists, public health experts, health economists) and prospectively follow-up more than 5000 patients with major mental disorders over a 9 month period. Across countries, we will compare the effectiveness and cost-effectiveness for clinical and social outcomes (including quality of life), patients health and social needs, safety and quality of care of patients in the two systems. We will also establish how patients and clinicians experience the advantages and limitations of each system, and identify the policies and legislative frameworks determining practice in the two systems. We will produce guidelines for policies specifying in what context and for which patient groups (e.g. older age) functional or integrated systems are preferable, and disseminate these widely (to governments, scientific societies, professional bodies, users and carers organizations).
Agency: Cordis | Branch: FP7 | Program: MC-ITN | Phase: FP7-PEOPLE-2012-ITN | Award Amount: 3.69M | Year: 2013
MARATONE is a Marie Curie Initial Training Network proposal that directly addresses the need for high-level training and career pathways in mental health to increase the inter-sectorial and trans-national employability of young scientists in the academic, public and private sectors to meet the enormous challenge of the 2009 EU Parliament Resolution on Mental Health. The Resolution set out recommendations for a comprehensive and integrated mental health strategy for Europe. MARATONE is designed to address the biggest challenge to implementing this ambitious strategy: the lack of training for career pathways for young scientists in multidisciplinary mental health research. MARATONE is built on the innovative theoretical premise of horizontal epidemiology, the view that psychosocial difficulties associated with mental health disorders are not exclusively determined by the diagnosis of the particular disorder in a vertical, silo-like pattern but horizontally in a manner that reflects commonalities in the lived experience of people with diverse mental health problems. Grounded in this theoretical foundation, MARATONEs multidisciplinary network of partners will collaboratively develop methodologies for measuring the individual and social impact of mental health disorders, so as to create strategies for the social and private sector responses to mental ill health in the form of health promotion and prevention programmes, and at the national level, strategies for human rights protections in policies and programming. The consortium will provide young researchers with scientific expertise in mental health, as well as basic technical and communication skills, including research development and management, international human rights commitments, and commercial exploitation and dissemination.
Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: SSH-2010-3.2-1 | Award Amount: 10.21M | Year: 2011
ALICE RAP is a Europe wide project of 43 partner research institutions involving 107 researchers from 25 European countries providing 1000 months of a plurality of scientific endeavour to analyse the place and challenges of addictions and lifestyles to the cohesion, organization and functioning of contemporary European society. Through integrated multidisciplinary research, a wide range of factors will be studied through a foresight approach to inform a redesign of effective addictions governance. Ownership will be described by an historical study of addiction through the ages, an analysis of public and private stakeholder views, and through image analyses, of professional and citizenship views. A study of how addictions are classified and defined will be followed by estimates of their health, social and economic impact. Determinants of addiction will be investigated through a coordinated and cohesive social, economic and biological analysis of initiation, transition into problem use and transition into and out of dependence. The business of addiction will be analyzed through studies of revenues, profits and participants in legal and illegal trade, the impact of suppliers on addictive substance use and behaviours, and analyses of webs of influence on policy responses. Addictions governance will be studied by describing the views and forces that determine the ways societies steer themselves and by stock taking of present governance practices to old and emerging addictions. Youth as customers will be analyzed through considering the impacts of new technologies on promoting and mitigating use, by studying the interrelations of culture and biology, and by determining features that promote resilience and nudge young people to reduce problematic use. The programme itself will be professionally managed from a partnership perspective to promote a coordinated and integrated approach to the high volume of research and its policy implications.
Agency: Cordis | Branch: FP7 | Program: CSA-CA | Phase: HEALTH-2009-2.2.1-5 | Award Amount: 1.68M | Year: 2010
The overall prevalence of brain disorders both neurological and psychiatric is very high in Europe. Although it is well known that the burden and costs of these disorders are high, there is evidence that the overall, personal, social and economic costs of brain disorders have been underestimated because of the lack of valid and reliable information regarding the full range of psychosocial difficulties that actually shape the lived experience of persons with these disorders and affect their quality of life. Current European data on psychosocial difficulties are derived from the diagnostic criteria of each disorder and so take the form of narrow information silos that are neither comprehensive nor comparable across disorders. Distinct information silos means that treatment planning, treatment evaluation and outcome assessment ignores commonalities of psychosocial consequences across disorders, undermining treatment efficiency and effectiveness, and ultimately increasing the costs of health and social care provision. The coordination action called PARADISE has the general objective of coordinating the development of a comprehensive and cross-cutting or horizontal epidemiology of psychosocial difficulties associated with brain disorders. Since a horizontal epidemiology accounts for the psychosocial difficulties that are actually experienced by people with brain disorders, independently of the brain disorder associated with them, it concentrates on what is more relevant to the lives of people with brain disorders. This leads to more effective intervention planning and management, and therefore to improved quality of life along the continuum of care, in the community, and across the life span. PARADISE coordinates the existing expertise in partners from eight European countries in relation to research literature, data documentation and analysis strategies for a representative range of brain disorders. These disorders are dementia, depression, epilepsy, migraine, multiple sclerosis, Parkinsons Disease, schizophrenia, stroke and substance use disorders. PARADISE will pave the way to future investigations that more meaningfully track the trajectories of psychosocial difficulties of brain disorders.